Post-transcriptional gene regulation by the RNA binding protein IGF2BP3 is critical for MLL-AF4 mediated leukemogenesis

Despite recent advances in therapeutic approaches, patients with MLL-rearranged leukemia still have poor outcomes and a high risk of relapse. Here, we found that MLL-AF4, the most common MLL fusion protein in patients, transcriptionally induces IGF2BP3 and that IGF2BP3 strongly amplifies MLL-Af4 mediated leukemogenesis. Deletion of Igf2bp3 significantly increases the survival of mice with MLL-Af4 driven leukemia and greatly attenuates disease, with a minimal impact on baseline hematopoiesis. At the cellular level, MLL-Af4 leukemia-initiating cells require Igf2bp3 for their function in leukemogenesis. eCLIP and transcriptome analysis of MLL-Af4 transformed stem and progenitor cells and MLL-Af4 bulk leukemia cells reveals a complex IGF2BP3-regulated post-transcriptional operon governing leukemia cell survival and proliferation. Regulated mRNA targets include important leukemogenic genes such as those in the Hoxa locus and numerous genes within the Ras signaling pathway. Together, our findings show that IGF2BP3 is an essential positive regulator of MLL-AF4 mediated leukemogenesis and represents an attractive therapeutic target in this disease.

[1]  Liu Jian,et al.  IGF2BP3 May Contributes to Lung Tumorigenesis by Regulating the Alternative Splicing of PKM , 2020, Frontiers in Bioengineering and Biotechnology.

[2]  H. Lacorazza,et al.  KLF4 Controls Leukemic Stem Cell Self-Renewal in MLL-AF9-Induced Acute Myeloid Leukemia , 2019, Blood.

[3]  Yifan Yang,et al.  ITGA6 and RPSA synergistically promote pancreatic cancer invasion and metastasis via PI3K and MAPK signaling pathways. , 2019, Experimental cell research.

[4]  Olga Tanaseichuk,et al.  Metascape provides a biologist-oriented resource for the analysis of systems-level datasets , 2019, Nature Communications.

[5]  A. Krainer,et al.  Targeting an RNA-Binding Protein Network in Acute Myeloid Leukemia. , 2019, Cancer cell.

[6]  I. Varela,et al.  Unraveling the cellular origin and clinical prognostic markers of infant B-cell acute lymphoblastic leukemia using genome-wide analysis , 2019, Haematologica.

[7]  B. Vick,et al.  JMJD1C-mediated metabolic dysregulation contributes to HOXA9-dependent leukemogenesis , 2019, Leukemia.

[8]  R. Janowski,et al.  Combinatorial recognition of clustered RNA elements by a multidomain RNA-binding protein, IMP3 , 2018, bioRxiv.

[9]  J. Downing,et al.  De novo activating mutations drive clonal evolution and enhance clonal fitness in KMT2A-rearranged leukemia , 2018, Nature Communications.

[10]  G. Hampton,et al.  A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types , 2018, npj Precision Oncology.

[11]  E. Clappier,et al.  The MLL recombinome of acute leukemias in 2017 , 2017, Leukemia.

[12]  J. Keaney,et al.  Hdac3 regulates lymphovenous and lymphatic valve formation , 2017, The Journal of clinical investigation.

[13]  Dong Chen,et al.  Blinatumomab-induced lineage switch of B-ALL with t(4:11)(q21;q23) KMT2A/AFF1 into an aggressive AML: pre- and post-switch phenotypic, cytogenetic and molecular analysis , 2017, Blood Cancer Journal.

[14]  J. Mulloy,et al.  The full transforming capacity of MLL-Af4 is interlinked with lymphoid lineage commitment. , 2017, Blood.

[15]  G. Basso,et al.  The lncRNA CASC15 regulates SOX4 expression in RUNX1-rearranged acute leukemia , 2017, Molecular Cancer.

[16]  B. Stecca,et al.  KLF4 is regulated by RAS/RAF/MEK/ERK signaling through E2F1 and promotes melanoma cell growth , 2017, Oncogene.

[17]  R. Stam,et al.  MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations , 2016, Oncotarget.

[18]  Salam A. Assi,et al.  Instructive Role of MLL-Fusion Proteins Revealed by a Model of t(4;11) Pro-B Acute Lymphoblastic Leukemia. , 2016, Cancer cell.

[19]  M. Valsecchi,et al.  Deciphering KRAS and NRAS mutated clone dynamics in MLL-AF4 paediatric leukaemia by ultra deep sequencing analysis , 2016, Scientific Reports.

[20]  B. Huntly,et al.  Mll-AF4 Confers Enhanced Self-Renewal and Lymphoid Potential during a Restricted Window in Development , 2016, Cell reports.

[21]  R. Mcmasters,et al.  Lineage Switch in MLL‐Rearranged Infant Leukemia Following CD19‐Directed Therapy , 2016, Pediatric blood & cancer.

[22]  B. Blencowe,et al.  IGF2BP3 Modulates the Interaction of Invasion-Associated Transcripts with RISC. , 2016, Cell reports.

[23]  Gary D Bader,et al.  miR-126 Regulates Distinct Self-Renewal Outcomes in Normal and Malignant Hematopoietic Stem Cells , 2016, Cancer cell.

[24]  Sol Katzman,et al.  RNA-binding protein IGF2BP3 targeting of oncogenic transcripts promotes hematopoietic progenitor proliferation. , 2016, The Journal of clinical investigation.

[25]  G. Boucher,et al.  The transcriptomic landscape and directed chemical interrogation of MLL-rearranged acute myeloid leukemias , 2015, Nature Genetics.

[26]  R. Marschalek,et al.  Subclonality and prenatal origin of RAS mutations in KMT2A (MLL)‐rearranged infant acute lymphoblastic leukaemia , 2015, British journal of haematology.

[27]  H. Dvinge,et al.  Widespread intron retention diversifies most cancer transcriptomes , 2015, Genome Medicine.

[28]  D. Casero,et al.  MicroRNA-146a modulates B-cell oncogenesis by regulating Egr1 , 2015, Oncotarget.

[29]  Michael G. Kharas,et al.  Musashi2 sustains the mixed-lineage leukemia-driven stem cell regulatory program. , 2015, The Journal of clinical investigation.

[30]  Cheng Cheng,et al.  The landscape of somatic mutations in Infant MLL rearranged acute lymphoblastic leukemias , 2015, Nature Genetics.

[31]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[32]  John T. Powers,et al.  Lin28b is sufficient to drive liver cancer and necessary for its maintenance in murine models. , 2014, Cancer cell.

[33]  P. Woll,et al.  Clonal variegation and dynamic competition of leukemia-initiating cells in infant acute lymphoblastic leukemia with MLL rearrangement , 2014, Leukemia.

[34]  T. Hansen,et al.  IMP3 RNP safe houses prevent miRNA-directed HMGA2 mRNA decay in cancer and development. , 2014, Cell reports.

[35]  Yidong Chen,et al.  A novel significance score for gene selection and ranking , 2014, Bioinform..

[36]  W. Hiddemann,et al.  The leukemogenicity of Hoxa9 depends on alternative splicing , 2014, Leukemia.

[37]  A. Jegga,et al.  MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1 , 2014, Oncogene.

[38]  V. Guryev,et al.  Insights in dynamic kinome reprogramming as a consequence of MEK inhibition in MLL-rearranged AML , 2014, Leukemia.

[39]  Gene W. Yeo,et al.  Rbfox proteins regulate alternative mRNA splicing through evolutionarily conserved RNA bridges , 2013, Nature Structural &Molecular Biology.

[40]  C. Lo Celso,et al.  Deciphering hematopoietic stem cells in their niches: a critical appraisal of genetic models, lineage tracing, and imaging strategies. , 2013, Cell stem cell.

[41]  Thomas A. Milne,et al.  RUNX1 Is a Key Target in t(4;11) Leukemias that Contributes to Gene Activation through an AF4-MLL Complex Interaction , 2013, Cell reports.

[42]  Reiko Nishihara,et al.  Insulin-like growth factor 2 messenger RNA binding protein 3 (IGF2BP3) is a marker of unfavourable prognosis in colorectal cancer. , 2012, European journal of cancer.

[43]  Janan T. Eppig,et al.  Supporting conditional mouse mutagenesis with a comprehensive cre characterization resource , 2012, Nature Communications.

[44]  J. Rowley,et al.  Two isoforms of HOXA9 function differently but work synergistically in human MLL-rearranged leukemia. , 2012, Blood cells, molecules & diseases.

[45]  Sean J Morrison,et al.  Cancer stem cells: impact, heterogeneity, and uncertainty. , 2012, Cancer cell.

[46]  Steven L Salzberg,et al.  Fast gapped-read alignment with Bowtie 2 , 2012, Nature Methods.

[47]  R. Bhatia,et al.  Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. , 2011, Blood.

[48]  S. Robson,et al.  Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia , 2011, Nature.

[49]  Hans Clevers,et al.  The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. , 2011, Cell stem cell.

[50]  M. Greaves,et al.  Enforced expression of MLL-AF4 fusion in cord blood CD34+ cells enhances the hematopoietic repopulating cell function and clonogenic potential but is not sufficient to initiate leukemia. , 2011, Blood.

[51]  L. Griškevičius,et al.  Identification of characteristic IGF2BP expression patterns in distinct B-ALL entities. , 2011, Blood cells, molecules & diseases.

[52]  A. Shilatifard,et al.  The super elongation complex (SEC) and MLL in development and disease. , 2011, Genes & development.

[53]  N. Miyake,et al.  Activated K-Ras protein accelerates human MLL/AF4-induced leukemo-lymphomogenicity in a transgenic mouse model , 2011, Leukemia.

[54]  C. Pui,et al.  Biology, risk stratification, and therapy of pediatric acute leukemias: an update. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  E. Wang,et al.  Analysis and design of RNA sequencing experiments for identifying isoform regulation , 2010, Nature Methods.

[56]  Ali Shilatifard,et al.  Licensed to elongate: a molecular mechanism for MLL-based leukaemogenesis , 2010, Nature Reviews Cancer.

[57]  Ryan M. O’Connell,et al.  Lentiviral Vector Delivery of Human Interleukin-7 (hIL-7) to Human Immune System (HIS) Mice Expands T Lymphocyte Populations , 2010, PloS one.

[58]  Ryan M. O’Connell,et al.  MicroRNA-34a perturbs B lymphocyte development by repressing the forkhead box transcription factor Foxp1. , 2010, Immunity.

[59]  C. Allis,et al.  Multiple interactions recruit MLL1 and MLL1 fusion proteins to the HOXA9 locus in leukemogenesis. , 2010, Molecular cell.

[60]  A. Krešo,et al.  Cancer Stem Cells and Self-renewal , 2010, Clinical Cancer Research.

[61]  C. Glass,et al.  Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. , 2010, Molecular cell.

[62]  S. Richards,et al.  Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial. , 2010, The Lancet. Oncology.

[63]  H. Kantarjian,et al.  Acute myeloid leukemia with t(9;11)(p21-22;q23): common properties of dysregulated ras pathway signaling and genomic progression characterize de novo and therapy-related cases. , 2010, American journal of clinical pathology.

[64]  T. Dingermann,et al.  The AF4.MLL fusion protein is capable of inducing ALL in mice without requirement of MLL.AF4. , 2010, Blood.

[65]  A. Shilatifard,et al.  AFF4, a component of the ELL/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia. , 2010, Molecular cell.

[66]  Aaron R. Quinlan,et al.  Bioinformatics Applications Note Genome Analysis Bedtools: a Flexible Suite of Utilities for Comparing Genomic Features , 2022 .

[67]  D. Huntsman,et al.  Insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3) overexpression in pancreatic ductal adenocarcinoma correlates with poor survival , 2010, BMC Cancer.

[68]  Irving L. Weissman,et al.  Association of reactive oxygen species levels and radioresistance in cancer stem cells , 2009, Nature.

[69]  Tina N. Davis,et al.  HOXA9 is required for survival in human MLL-rearranged acute leukemias. , 2009, Blood.

[70]  D. Huntsman,et al.  IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype , 2009, Modern Pathology.

[71]  Howard Y. Chang,et al.  Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared with embryonic rather than adult stem cells. , 2009, Cell stem cell.

[72]  Xiaobo Xia,et al.  H3K79 methylation profiles define murine and human MLL-AF4 leukemias. , 2008, Cancer cell.

[73]  A. Eychène,et al.  A new MAFia in cancer , 2008, Nature Reviews Cancer.

[74]  Korbinian Strimmer,et al.  A unified approach to false discovery rate estimation , 2008, BMC Bioinformatics.

[75]  Korbinian Strimmer,et al.  fdrtool: a versatile R package for estimating local and tail area-based false discovery rates , 2008, Bioinform..

[76]  Yi Zheng,et al.  Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia. , 2008, Cancer cell.

[77]  Scott A. Armstrong,et al.  MLL translocations, histone modifications and leukaemia stem-cell development , 2007, Nature Reviews Cancer.

[78]  J. Fisher,et al.  Unique and independent roles for MLL in adult hematopoietic stem cells and progenitors. , 2007, Cell stem cell.

[79]  Suzanne Schubbert,et al.  Hyperactive Ras in developmental disorders and cancer , 2007, Nature Reviews Cancer.

[80]  J. Keene.  RNA regulons: coordination of post-transcriptional events , 2007, Nature Reviews Genetics.

[81]  Mark W. Dewhirst,et al.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response , 2006, Nature.

[82]  M. Cleary,et al.  Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. , 2006, Cancer cell.

[83]  T. Golub,et al.  Transformation from committed progenitor to leukaemia stem cell initiated by MLL–AF9 , 2006, Nature.

[84]  N. Kirchhof,et al.  A murine Mll-AF4 knock-in model results in lymphoid and myeloid deregulation and hematologic malignancy. , 2006, Blood.

[85]  T. Rabbitts,et al.  A conditional model of MLL-AF4 B-cell tumourigenesis using invertor technology , 2006, Oncogene.

[86]  M. D. Boer,et al.  The MLL recombinome of acute leukemias , 2006, Leukemia.

[87]  I. Weissman,et al.  Loss of expression of the Hoxa-9 homeobox gene impairs the proliferation and repopulating ability of hematopoietic stem cells. , 2005, Blood.

[88]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[89]  H. Koga,et al.  Constitutive activation of the mitogen-activated protein kinase signaling pathway in acral melanomas. , 2005, The Journal of investigative dermatology.

[90]  Jack D. Keene,et al.  Post-transcriptional operons and regulons co-ordinating gene expression , 2005, Chromosome Research.

[91]  L. Zon,et al.  An Mll-Dependent Hox Program Drives Hematopoietic Progenitor Expansion , 2004, Current Biology.

[92]  S. Korsmeyer,et al.  Definitive hematopoiesis requires the mixed-lineage leukemia gene. , 2004, Developmental cell.

[93]  Nansheng Chen,et al.  Using RepeatMasker to Identify Repetitive Elements in Genomic Sequences , 2009, Current protocols in bioinformatics.

[94]  W. Alexander,et al.  SOCS3 is a critical physiological negative regulator of G-CSF signaling and emergency granulopoiesis. , 2004, Immunity.

[95]  M. Daly,et al.  PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes , 2003, Nature Genetics.

[96]  T. Seufferlein,et al.  KOC is a novel molecular indicator of malignancy , 2003, British Journal of Cancer.

[97]  Mark Coles,et al.  Transgenic mice with hematopoietic and lymphoid specific expression of Cre , 2003, European journal of immunology.

[98]  J. Downward.  Targeting RAS signalling pathways in cancer therapy , 2003, Nature Reviews Cancer.

[99]  D. Charnock-Jones,et al.  vavCre Transgenic mice: A tool for mutagenesis in hematopoietic and endothelial lineages , 2002, Genesis.

[100]  T. Imamura,et al.  Frequent co‐expression of HoxA9 and Meis1 genes in infant acute lymphoblastic leukaemia with MLL rearrangement , 2002, British journal of haematology.

[101]  C. Croce,et al.  Upregulation of Meis1 and HoxA9 in acute lymphocytic leukemias with the t(4 : 11) abnormality , 2001, Oncogene.

[102]  R. Hardy,et al.  B cell development pathways. , 2001, Annual review of immunology.

[103]  M. Beil,et al.  Expression of the highly conserved RNA binding protein KOC in embryogenesis , 1999, Mechanisms of Development.